JP2024521979A5 - - Google Patents

Info

Publication number
JP2024521979A5
JP2024521979A5 JP2024517826A JP2024517826A JP2024521979A5 JP 2024521979 A5 JP2024521979 A5 JP 2024521979A5 JP 2024517826 A JP2024517826 A JP 2024517826A JP 2024517826 A JP2024517826 A JP 2024517826A JP 2024521979 A5 JP2024521979 A5 JP 2024521979A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521979A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/023210 external-priority patent/WO2022250170A1/en
Publication of JP2024521979A publication Critical patent/JP2024521979A/ja
Publication of JP2024521979A5 publication Critical patent/JP2024521979A5/ja
Pending legal-status Critical Current

Links

JP2024517826A 2021-05-28 2022-05-27 Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照 Pending JP2024521979A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194852P 2021-05-28 2021-05-28
US63/194,852 2021-05-28
PCT/JP2022/023210 WO2022250170A1 (en) 2021-05-28 2022-05-27 Small molecule inhibitors of kras mutated proteins

Publications (2)

Publication Number Publication Date
JP2024521979A JP2024521979A (ja) 2024-06-04
JP2024521979A5 true JP2024521979A5 (enExample) 2025-06-02

Family

ID=82403667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517826A Pending JP2024521979A (ja) 2021-05-28 2022-05-27 Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照

Country Status (5)

Country Link
US (1) US20240317759A1 (enExample)
EP (1) EP4347041A1 (enExample)
JP (1) JP2024521979A (enExample)
CN (1) CN117769554A (enExample)
WO (1) WO2022250170A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI831855B (zh) 2018-10-26 2024-02-11 日商大鵬藥品工業股份有限公司 新穎吲唑化合物或其鹽
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021106230A1 (ja) 2019-11-29 2021-06-03 大鵬薬品工業株式会社 新規なフェノール化合物又はその塩
EP4262803A4 (en) * 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
JP2025541682A (ja) 2022-11-21 2025-12-23 ツリーライン バイオサイエンシズ インコーポレイテッド スピロ環式ジヒドロピランピリミジンＫＲａｓ阻害剤
TW202504599A (zh) 2023-06-30 2025-02-01 美商必治妥美雅史谷比公司 Kras抑制劑
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202515570A (zh) 2023-08-17 2025-04-16 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ｋｒａｓ抑制劑
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
AU2024344161A1 (en) 2023-09-21 2026-03-26 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
PT734389E (pt) 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
AU702522B2 (en) 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
CA2260898C (en) 1996-07-18 2002-05-14 Pfizer Limited Phosphinate based inhibitors of matrix metalloproteases
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
DE69730151T2 (de) 1997-01-06 2005-08-04 Pfizer Inc. Cyclische sulfonderivate
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
ID23668A (id) 1997-08-08 2000-05-11 Pfizer Prod Inc Turunan asam ariloksiarilsulfonilamino hidroksamat
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP1259595B1 (en) 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
WO2005005434A1 (en) 2003-07-08 2005-01-20 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CN101039952A (zh) 2004-10-13 2007-09-19 惠氏公司 作为pi3k抑制剂的17－羟基渥曼青霉素类似物
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2622870A1 (en) 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
MX2012007367A (es) 2009-12-30 2013-04-03 Arqule Inc Compuestos substituidos de imidazopiridinilo-aminopiridina.
ES2567605T3 (es) 2011-04-06 2016-04-25 Taiho Pharmaceutical Co., Ltd. Nuevo compuesto de imidazo-oxazina o sal del mismo
EP2723741B8 (en) 2011-06-24 2016-09-21 ArQule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
SG11201601616SA (en) 2013-09-09 2016-04-28 Peloton Therapeutics Inc Aryl ethers and uses thereof
US10457669B2 (en) 2015-10-21 2019-10-29 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
CN109843856B (zh) * 2016-05-18 2023-05-02 米拉蒂治疗股份有限公司 Kras g12c抑制剂
KR102861303B1 (ko) * 2017-11-15 2025-09-17 미라티 테라퓨틱스, 인크. Ｋｒａｓ ｇ12ｃ 억제제
KR102753101B1 (ko) 2018-03-02 2025-01-09 오츠카 세이야쿠 가부시키가이샤 약제학적 화합물
SG11202100719YA (en) 2018-07-24 2021-02-25 Taiho Pharmaceutical Co Ltd Heterobicyclic compounds for inhibiting the activity of shp2
TW202110837A (zh) * 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
US20210040089A1 (en) * 2019-08-07 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors
CA3148745A1 (en) * 2019-08-29 2021-03-04 Xiaolun Wang Kras g12d inhibitors
CN112442029A (zh) * 2019-09-04 2021-03-05 四川海思科制药有限公司 一种四氢吡啶并[3,4-d]嘧啶衍生物及其在医药上的应用
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN113004269B (zh) * 2019-12-19 2024-11-05 首药控股(北京)股份有限公司 Kras-G12C抑制剂杂环化合物
CN113045565A (zh) * 2019-12-27 2021-06-29 微境生物医药科技(上海)有限公司 新型K-Ras G12C抑制剂
CN113135924B (zh) * 2020-01-19 2024-04-26 广东东阳光药业股份有限公司 嘧啶衍生物及其在药物中的应用
CN116194456B (zh) * 2020-04-30 2025-08-29 上海科州药物股份有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
US20230357277A1 (en) * 2020-09-22 2023-11-09 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262803A4 (en) * 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CN117120058A (zh) * 2021-02-09 2023-11-24 金橘生物科技公司 杂环化合物及其用途
CN116801883A (zh) * 2021-03-18 2023-09-22 四川科伦博泰生物医药股份有限公司 一类杂芳环化合物、其制备方法及用途
CN117203208A (zh) * 2021-04-23 2023-12-08 清华大学 靶向活化与失活态kras g12d的抑制剂

Similar Documents

Publication Publication Date Title
EP4017489B1 (en) Dgd1202 for use in the treatment of kras-mutated cancers
JP5579715B2 (ja) ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
CN108366992A (zh) 蛋白水解靶向嵌合体化合物及其制备和应用方法
CA3156135A1 (en) PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS
RU2021103727A (ru) Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
JP2019518046A5 (enExample)
RU2000127020A (ru) Производные имидазопиридина, ингибирующие секрецию желудочной кислоты
KR20090013827A (ko) Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
JPWO2021060453A5 (enExample)
WO2022143628A1 (zh) 预防或治疗抗肿瘤剂相关疾病或病症的方法
AU2018360559B2 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLXL inhibitors, and BCLXL inhibitors and methods of use
WO2016014783A1 (en) Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
US10358447B2 (en) Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
US12551484B2 (en) Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
WO2021097075A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
CA3113408A1 (en) Cancer combination therapy using quinoline carboxamide derivative
JP7763761B2 (ja) Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法
JP2008517065A (ja) Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法
US20160095859A1 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
TW202617705A (zh) 作為cyp11a1抑制劑之雜環化合物
JP6243844B2 (ja) トロンビン受容体アンタゴニストを有効成分とする肺高血圧症の予防治療剤